XNCR:NSD-Xencor Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 23.72

Change

-0.41 (-1.70)%

Market Cap

USD 1.08B

Volume

0.90M

Analyst Target

USD 45.64
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xencor Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.83 (+1.45%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+14.04 (+1.96%)

USD 78.92B
ARGX argenx NV ADR

+3.25 (+0.50%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+2.80 (+1.20%)

USD 30.22B
MRNA Moderna Inc

+4.96 (+11.65%)

USD 16.10B
UTHR United Therapeutics Corporatio..

+6.94 (+1.95%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.29 (+1.13%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.69 (+3.95%)

USD 13.43B
INCY Incyte Corporation

+1.28 (+1.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.83 (+1.24%)

USD 12.74B

ETFs Containing XNCR

CNCR Loncar Cancer Immunothera.. 1.88 % 0.79 %

+0.02 (+0.14%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.22% 41% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.22% 41% F 63% D
Trailing 12 Months  
Capital Gain 12.68% 73% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.68% 73% C 64% D
Trailing 5 Years  
Capital Gain -35.10% 66% D+ 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.10% 66% D+ 30% F
Average Annual (5 Year Horizon)  
Capital Gain -8.51% 35% F 22% F
Dividend Return -8.51% 35% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.01% 93% A 70% C-
Risk Adjusted Return -34.05% 27% F 18% F
Market Capitalization 1.08B 86% B+ 77% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.30 12% 15%
Price/Book Ratio 2.35 49% 44%
Price / Cash Flow Ratio 19.97 4% 16%
Price/Free Cash Flow Ratio -17.27 95% 93%
Management Effectiveness  
Return on Equity -29.02% 84% 40%
Return on Invested Capital -20.38% 76% 34%
Return on Assets -15.24% 82% 29%
Debt to Equity Ratio 2.19% 72% 82%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.